ACG Wealth’s BioNTech BNTX Stock Holding History

ACG Wealth’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-101	Closed	-$15K	–	325
2022 Q2	$15K	Buy	+101	New	+$15.4K	﹤0.01%	621

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ACG Wealth's BNTX Position: Q3 2022 in Review

ACG Wealth sold out of BioNTech (BNTX) in Q3 2022, closing a stake of 101 shares — an estimated $15K sold.

ACG Wealth first reported a position in BNTX in Q2 2022 and held it in 1 quarter. The position peaked at $15K in Q2 2022. 264 funds tracked by Wall St. Rank hold BNTX as of Q3 2022.

ACG Wealth reported no remaining BioNTech position as of Q3 2022 after selling out during the quarter.
ACG Wealth sold 101 BioNTech shares in Q3 2022, an estimated $15K.
ACG Wealth first reported a position in BioNTech in Q2 2022 and held it in 1 quarter.
ACG Wealth's BioNTech position peaked at $15K in Q2 2022.
264 funds tracked by Wall St. Rank held BioNTech as of Q3 2022.

Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.